Q-Line Biotech Limited

<table><tr><td>Net asset value per share(A/D) (Face Value of Rs. 10 Each) Based on actual number of shares - Before considering Bonus issue of share</td><td>1,206.00</td><td>1,027.39</td><td>808.67</td></tr><tr><td>Net asset value per share (A/F) (Face Value of Rs. 10 Each) Based on on Weighted number of shares - After considering Bonus Issue of Shares</td><td>120.60</td><td>102.74</td><td>80.87</td></tr><tr><td>Restated Earnings Before Interest Tax Depreciation and Amortisation (EBITDA)</td><td>7,132.12</td><td>3,762.50</td><td>3,297.72</td></tr></table>

Notes:

1) The ratios have been computed as below:

(a) Basic earnings per share (Rs. ) - : Net profit after tax as restated for calculating basic EPS / Weighted average number of equity shares outstanding at the end of the period or year

(b) Diluted earnings per share (Rs. ) - : Net profit after tax as restated for calculating diluted EPS / Weighted average number of equity shares outstanding at the end of the period or year for diluted EPS

(c) Earnings per share (Rs.) Before extra Ordinary Items means PAT as adjusted for extra ordinary item to eliminate the impact of Extra Ordinary item in current period PAT.

(d) Return on net worth (%) -: Net profit after tax (as restated) / Net worth at the end of the period or year

(e) Net assets value per share -: Net Worth at the end of the period or year / Total number of equity shares outstanding at the end of the period or year

(f) EBITDA has been calculated as Profit before Tax+Depreciation+Interest Expenses-Other Income+Exceptional Gain(loss)+Extraordinary Items

2) Weighted average number of equity shares is the number of equity shares outstanding at the beginning of the period/year adjusted by the number of equity shares issued during period/year multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the period/year.

3) Net worth for ratios mentioned is equals to Equity share capital + Reserves and surplus ( including, Securities Premium, General Reserve and surplus in statement of profit and loss.

4) The figures disclosed above are based on the restated summary statements.

5) The above statement should be read with the significant accounting policies and notes to restated summary statements of assets and liabilities, profits and losses and cash flows appearing in Annexures IV, I, II and III

2. The Authorised Share Capital of the Company was increased from ₹400 Lakhs divided into 40,00,000 no. of equity shares of ₹ 10 each to ₹ 2500 Lakhs divided into 250,00,000 no. of equity shares of ₹ 10 each, purusnat to the approval of the Extra Ordinary General meeting held on 01st August, 2025.

3. The company issued 1,41,75,000 Equity shares as Bonus to the approval of the Extra Ordinary General Meeting held on 28th August 2025 to existing shareholder in the ratio of 9:1.

ANNEXURE – X

RESTATED CONSOLIDATED STATEMENT OF RELATED PARTY TRANSACTION

(Amount in Rs. Lakhs)

Lis of Related Parties as per AS – 18

<table><thead><tr><th>Particulars</th><th>Names of related parties</th><th>Nature of Relationship</th></tr></thead><tbody><tr><td rowspan="10">Directors and Key Management Personnel (KMP)</td><td>Saurabh Garg</td><td>Promoter, Managing Director and Chairman</td></tr><tr><td>Amita Garg</td><td>Promoters and Non-Executive Director</td></tr><tr><td>Ajay Kumar Mahanty</td><td>Whole- Time Director</td></tr><tr><td>Ayush Garg</td><td>Promoters &amp; Non-Executive Director</td></tr><tr><td>Kuldeep Chowdhry</td><td>Whole- Time Director</td></tr><tr><td>Abhay Agarwal</td><td>Promoters &amp; Non-Executive Director</td></tr><tr><td>Manisha Yadav</td><td>Directorship(removed w.e.f 18th April 2024)</td></tr><tr><td>Pravir Kumar</td><td>Independent Director (w.e.f. 08th May, 2025)</td></tr><tr><td>Rohit Nandan</td><td>Independent Director (w.e.f. 08th May, 2025)</td></tr><tr><td>Jai Prakash Singh</td><td>Independent Director (w.e.f. 01st August, 2025)</td></tr></tbody></table>

227